Form 4: Forte Biosciences Director Acquires Stock Options

Director Shivpreet Singh Kapoor acquires stock options in Forte Biosciences, Inc.

Summary

• On March 20, 2025, Shivpreet Singh Kapoor, a director of Forte Biosciences, Inc., acquired 31,000 stock options.
• The options have an exercise price of $7.54.
• The options vest in equal monthly installments over three years, becoming fully vested on March 20, 2028, contingent upon continued service as a Service Provider.
• The options expire on March 20, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance, but rather aligns the director's interests with the company's.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biotechnology industry where equity compensation is frequently used.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, particularly in the biotech sector, to align their interests with those of shareholders.
• The vesting schedule of three years is also fairly standard.
• Comparable companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their compensation packages for directors and executives.

Stakeholder Impact

• The granting of stock options to a director can potentially align the director's interests with those of the shareholders.

Key Dates

Keywords

Forte Biosciences, Stock Options, Director, Acquisition, Equity, FBRX, Shivpreet Singh Kapoor